SoylentNews is people
SoylentNews
The FDA has approved a new drug for Alzheimer's disease, while not a cure it is supposed to slow the decline. Even though data is not entirely positive or straight forward in its interpretation or that it will actually even work as thought.
But if you have it then you are probably desperate enough to try almost anything that claims to work, until you get to the price tag of $56,000 per year. That will probably make it out of reach for most people, it's doubtful if any insurance will cover something like this. Perhaps you can just forget to pay the bill, they might understand due to your condition.
Biogen CEO Michel Vounatsos [...][said] he thought the drug's price was "fair" but also vowed that the company would not hike its price for four years.
Previously:
In Surprise Turnaround, Biogen to Submit Previously Failed Alzheimer Drug for Approval
Disputed Alzheimer's Study Links Decrease in Amyloid Levels to Reduction in Cognitive Decline
Positive Result in Mice as Alzheimer's Drug Trials Fail and Regulatory Barriers Are Rolled Back
(Score: 3, Informative) by Runaway1956 on Wednesday June 09 2021, @09:59PM (4 children)
A couple quick searches gave me these:
https://arstechnica.com/science/2019/01/healthcare-industry-spends-30b-on-marketing-most-of-it-goes-to-doctors/ [arstechnica.com]
https://www.prescouter.com/2019/06/pharmaceutical-rd-global-spending-trends-in-2019/ [prescouter.com]
So, 20 billion for advertising, vs 165 billion for R&D. No indication of lobbying and campaign donation costs.
(Score: -1, Flamebait) by Anonymous Coward on Wednesday June 09 2021, @10:12PM
Oh Noes! Moar Runaway Education? Lord save us!
(Score: 2) by Beryllium Sphere (r) on Thursday June 10 2021, @12:11AM
Thank you.
(Score: 2) by PiMuNu on Thursday June 10 2021, @11:33AM
Interesting post
(Score: 0) by Anonymous Coward on Friday June 11 2021, @09:41PM
A couple of problems here. You are comparing only the amount of money spent only on wooing doctors in the US while leaving out all other marketing activities worldwide to total worldwide R&D both public and private.
But where the money has really gone for huge pharmacology corporations is to stock buybacks. There are a number of articles on that and a recent clip of CEOs getting grilled over where their money goes by a congresswoman a few days ago.